+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 85Years
All Genders
ID06053164

Evaluating Portable Oxygen Therapy and Support for Adults With Mild-to-Moderate Fibrotic Interstitial Lung Disease

Led by University of Alberta · Updated on 2026-10-23

60

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating whether portable oxygen therapy during physical activity can improve quality of life, exercise tolerance, shortness of breath, and blood vessel function in patients with fibrotic interstitial lung disease ILD who have normal oxygen levels at rest but develop low oxygen levels with exertion. This study also explores whether adding personalized support through phone calls and educational materials enhances the benefits of oxygen therapy. The study is a phase 2, randomized controlled trial aiming to assess both feasibility and clinical effects. Participants will be randomly assigned to one of three groups for an 8-week period usual care with no supplemental oxygen, supplemental oxygen during exertion, or supplemental oxygen plus educational support and scheduled phone check-ins with a respiratory educator. Before the intervention, there is a 2-week baseline period, and after the intervention, a 2-week washout period. Study visits include assessments of lung function, exercise tests, vascular function measurements, blood tests, and questionnaires. Participants will attend seven sessions over about 13 weeks, including baseline testing, intervention, and follow-up visits. They will wear activity and oxygen monitors to track daily physical activity and oxygen levels. Researchers will measure outcomes such as health-related quality of life, exercise tolerance, dyspnea, cough, vascular function, pulmonary artery pressure, cardiac function, and systemic inflammation. The total time commitment for each participant is approximately 12 hours.

CONDITIONS

Brief Title

Ambulatory Oxygen Therapy for Individuals With Mild-to-moderate Interstitial Lung Disease

Research Team

M

Matt Rieger, PhD

D

Desi Fuhr, MSc

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here